Search
for

    Learn

    5 / 801 results

    Research

    5 / 344 results

    Community Join

    5 / 1000+ results

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

      community Pp405 phase 2a clinical results

      in Research/Science  40 upvotes 11 months ago
      PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

      community Any experiences with Ptd-dbm??

      in Research/Science  5 upvotes 2 weeks ago
      The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.